Table 11: Evidence-based drugs and oral doses as shown in large clinical trials
| ACEI Drugs |
| Enalapril |
| Start Dose: 1.25-2.5 mg BID |
| Target Dose: 10 mg BID/ 20 BID in NYHA class IV |
| Lisinopril |
| Start Dose: 2.5-5 mg daily |
| Target Dose: 20-35 mg daily |
| Perindopril |
| Start Dose: 2-4 mg |
| Target Dose: 4-8 mg |
| Ramipril |
| Start Dose: 1.25-2.5 mg BID |
| Target Dose: 5 mg BID |
| Trandolapril |
| Start Dose: 1-2 mg daily |
| Target Dose: 4 mg daily |
| ARB Drugs |
| Candesartan |
| Start Dose: 4-8 mg daily |
| Target Dose: 32 mg daily |
| Valsartan |
| Start Dose: 40 mg BID |
| Target Dose: 160 mg BID |
| Beta-blockers Drugs |
| Carvedilol |
| Start Dose: 3.125mg BID |
| Target Dose: 25mg BID, 50mg BID (> 85kg) |
| Bisoprolol |
| Start Dose: 1.25mg daily |
| Target Dose: 10mg daily |
| Metoprolol CR/XL* |
| Start Dose: 12.5-25mg daily |
| Target Dose: 200mg daily |
| MRA Drugs |
| Spironolactone |
| Start Dose: 12.5mg daily |
| Target Dose: 50 mg daily |
| Eplerenone |
| Start Dose: 25 mg daily |
| Target Dose: 50 mg daily |
| ARNI Drugs |
| Sacubutril/Valsartan |
| Start Dose: 50-100 mg BID |
| Target Dose: 200 mg BID |
| If Inhibitor Drugs |
| Ivabradine |
| Start Dose: 2.5-5 mg BID |
| Target Dose: 7.5 mg BID |
| Vasodilators Drugs |
| Isosorbide dinitrate |
| Start Dose: 20 mg TID |
| Target Dose: 40 mg TID |
| Hydralazine |
| Start Dose: 37.5 mg TID |
| Target Dose: 75-100 mg TID-QID |
* Limited evidence of short acting metoprolol tartrate in HF. Metoprolol CR/XL is not available in Canada.
ACEi, angiotensin-converting enzyme inhibitor;
ARB, angiotensin receptor blocker;
ARNI, angiotensin receptor-neprilysin inhibitor;
BID, twice per day;
CR/XL, Controlled Release/Extended Release;
HF, heart failure;
If, Inhibiting f-channel;
MRA, mineralocorticoid receptor antagonist;
NYHA, New York Heart Association;
QID, 4 times per day;
TID, 3 times per day.